Bone Mineral Density News and Research

RSS

Current celiac disease screening method more cost-effective than universal screening, study finds

The current standard practice of screening adolescents who are either symptomatic or at high-risk for celiac disease proves to be more cost-effective than universal screening. Additionally, the strategy is successful in preventing bone loss and fractures in celiac patients, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

11 Jun 2013

Prostate cancer patients need to be aware of the effects of androgen deprivation therapy

Androgen deprivation therapy is a common and effective treatment for advanced prostate cancer. However, among other side-effects, it can cause significant bone thinning in men on long-term treatment.

15 May 2013

New version of FRAX now available for 53 countries

An increasing number of physicians around the world are using FRAX-, a scientifically validated online fracture-risk calculator that has been developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases at the University of Sheffield, UK.

8 May 2013

Study shows smoking and depression in adolescent girls have negative impact on bone mineral density

First-Time Study Shows Smoking and Depression in Adolescents have Negative Impact on Bone Mineral Density, say Investigators in the Journal of Adolescent Health

4 Apr 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

$Exercise interventions in childhood are associated with lower fracture risks in old age$

Exercise interventions in childhood are associated with lower fracture risks in old age

Get out there and regularly kick that soccer ball around with your kids, you may be helping them prevent a broken hip when they are older, say researchers presenting their work at the American Orthopaedic Society for Sports Medicine's (AOSSM) Specialty Day in Chicago, IL.

25 Mar 2013

New guidance highlights risk factors and treatments for osteoporosis in postmenopausal women

A new Guidance recently published by the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the International Osteoporosis Foundation (IOF) reflects the most current advances in the diagnosis and management of osteoporosis, the 'silent disease' which affects up to one in two postmenopausal women.

25 Mar 2013

Maternal vitamin D levels not found to affect children’s bone health

A study of nearly 4000 pairs of mothers and their children in the Children of the 90s study at the University of Bristol has shown that maternal vitamin D levels during pregnancy are not associated with the child’s bone health in later life. The research, published Online First in The Lancet, is the largest ever observational study of the effects of mothers’ vitamin D levels in pregnancy on their children’s bone health, and suggests that UK health guidelines may be overstating the importance of vitamin D supplementation in pregnancy.

20 Mar 2013

Researchers uncover clear genetic link between fat and bone mass

When it comes to body shape, diet and exercise can only take us so far. Our body shape and geometry are largely determined by genetic factors. Genetics also have an impact on our body composition - including soft fat tissue and hard bone tissue - and can lead to excess fat or osteoporosis.

12 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Dairy intake may increase risk of bone mineral density in the hip

A study by researchers at the Institute for Aging Research (IFAR) at Hebrew SeniorLife, an affiliate of Harvard Medical School (HMS), has found that dairy intake -specifically milk and yogurt -is associated with higher bone mineral density (BMD) in the hip, but not the spine.

1 Feb 2013

$ADT increases risk of fracture incidence after treatment completion in men with prostate cancer$

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.

18 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Extended steroid treatment fails to reduce pediatric nephrotic relapse

Study findings indicate that extending initial prednisolone treatment durations in patients with pediatric nephrotic syndrome from 3 to 6 months without increasing the overall dose does not reduce the number of relapses.

22 Dec 2012

Osteoporosis screening: an interview with Professor Cyrus Cooper

Osteoporosis is defined as a reduction in bone mass coupled with micro-architectural deterioration of bone tissue which predisposes to fractures. Osteoporosis manifests through an increased risk of fracture, and age-related fractures are a major public health problem.

17 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

Complex process of bone disease evident in mastocytosis

Patients with mastocytosis show elevated bone turnover that is associated with a higher mast cell load and advanced disease relative to individuals without the condition, suggest study findings.

12 Dec 2012

Teenage girls who smoke may put themselves at risk for osteoporosis

Adolescent girls who smoke between the ages of 11 and 19 years may be putting themselves at increased risk for osteoporosis in older age, suggest study results.

6 Dec 2012